Physician profile
Katherine L Mccormack
NPI 1194085183
$89,508.85
in general payments reported to CMS, 2019-2025
27 companies · $68K in 2025
The $68K reported for 2025 was more than what 97% of Allergy & Immunology providers received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $713 · 2020: $147 · 2021: $2,627 · 2022: $3,977 · 2023: $1,783 · 2024: $12K · 2025: $68K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $60K · Consulting Fee: $8,706 · Food and Beverage: $6,549 · Travel and Lodging: $6,353 · Education: $124.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $60,313.00 |
| Consulting Fee | $8,706.00 |
| Food and Beverage | $6,549.15 |
| Travel and Lodging | $6,352.64 |
| Education | $123.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $67,362.19 | 2019-2025 | |
| Ars Pharmaceuticals Operations, INC. | $14,876.28 | 2025 | Neffy |
| Genentech USA, INC. | $2,237.62 | 2021-2025 | Xolair |
| Astrazeneca Pharmaceuticals Lp | $1,948.85 | 2019-2025 | Tezspire, Fasenra, Breztri |
| Glaxosmithkline, LLC. | $666.27 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Regeneron Healthcare Solutions, INC. | $607.46 | 2019-2025 | Dupixent |
| Pharming Healthcare, INC. | $196.80 | 2021-2025 | Ruconest |
| Pfizer INC. | $168.59 | 2019-2025 | |
| Blueprint Medicines Corporation | $164.07 | 2023 | Ayvakit |
| Kaleo, INC. | $163.84 | 2020-2022 | |
| Optinose US, INC. | $162.98 | 2019-2022 | |
| Alk-Abello, INC | $153.22 | 2021-2023 | Grastek, Odactra, Ragwitek |
| Biocryst US Sales Co., LLC | $146.55 | 2023-2025 | Orladeyo |
| Genentech, INC. | $145.98 | 2025 | Xolair |
| Takeda Pharmaceuticals U.S.A., INC. | $125.50 | 2022-2025 | Hyqvia, Cuvitru, Eohilia |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $62.46 | 2022-2023 | Tezspire |
| Novartis Pharmaceuticals Corporation | $59.57 | 2019-2025 | |
| Grifols USA, LLC | $59.09 | 2019-2023 | Xembify |
| Organon LLC | $40.61 | 2025 | Vtama |
| Csl Behring | $31.83 | 2025 | Hizentra |
| Aimmune Therapeutics, INC. | $23.16 | 2022 | |
| Incyte Corporation | $20.14 | 2023 | Opzelura |
| Uswm, LLC | $20.00 | 2021 | |
| Circassia INC. | $19.44 | 2019 | |
| Sanofi-Aventis U.S. LLC | $17.97 | 2020 | |
| Galderma Laboratories, L.P. | $16.00 | 2025 | Nemluvio |
| Teva Pharmaceuticals USA, INC. | $12.38 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Katherine Mccormack listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.